tiprankstipranks
Trending News
More News >
Nath Bio-Genes (India) Ltd. (IN:NATHBIOGEN)
:NATHBIOGEN
India Market
Advertisement

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

Compare
3 Followers

Top Page

IN:NATHBIOGEN

Nath Bio-Genes (India) Ltd.

(NATHBIOGEN)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 4o)
Rating:65Neutral
Price Target:
₹182.00
▲(7.63% Upside)
Nath Bio-Genes' overall stock score is driven by its strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which could pose short-term risks. The absence of earnings call and corporate event data limits the analysis to these factors.

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company DescriptionNath Bio-Genes (India) Ltd. (NATHBIOGEN) is a leading agricultural biotechnology company based in India, specializing in the development and production of hybrid seeds and agricultural inputs. The company operates primarily in the field of seed genetics and crop production, offering a diverse range of products including cotton, maize, and various vegetable seeds. NATHBIOGEN is committed to enhancing agricultural productivity through innovative research and development, focusing on sustainability and quality in agriculture.
How the Company Makes MoneyNath Bio-Genes generates revenue primarily through the sale of hybrid seeds and related agricultural products. Its revenue model is anchored in the development and commercialization of high-yield and pest-resistant seed varieties, which are sold to farmers across India and potentially in international markets. Key revenue streams include sales from hybrid seeds, as well as associated products such as fertilizers and crop protection chemicals which complement their seed offerings. The company also benefits from partnerships with agricultural research institutions and collaborations with other agribusiness companies, enhancing its R&D capabilities and expanding its market reach. Seasonal demand for seeds, driven by planting cycles and agricultural trends, significantly influences the company's earnings, alongside potential government policies supporting agricultural innovation.

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary
Nath Bio-Genes has a strong profitability profile with healthy profit margins and revenue growth. The balance sheet shows financial stability with low debt and improved return on equity. However, there is variability in EBIT, EBITDA margins, and free cash flow, which could impact liquidity.
Income Statement
72
Positive
The company shows a solid performance in terms of profitability with a healthy gross profit margin and stable net profit margin. Revenue growth from 2024 to 2025 was significant, indicating a positive trajectory. However, EBIT and EBITDA margins have shown slight fluctuations over the years, suggesting some variability in operating efficiency.
Balance Sheet
68
Positive
Nath Bio-Genes maintains a strong equity base with a relatively low debt-to-equity ratio, indicating financial stability. The return on equity has improved, reflecting effective use of shareholder funds. However, the equity ratio indicates a moderate reliance on debt, which could pose risks if not managed carefully.
Cash Flow
65
Positive
The cash flow statement reflects a positive trend in free cash flow growth, indicating improved cash generation from operations. The operating cash flow to net income ratio suggests efficient conversion of income into cash. However, the free cash flow to net income ratio has shown variability, which may affect liquidity.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.05B3.65B2.48B3.01B2.78B3.07B
Gross Profit2.13B2.29B1.03B1.67B1.54B1.71B
EBITDA577.27M497.98M536.39M488.91M-497.06M684.33M
Net Income425.26M386.00M396.19M350.11M-673.38M556.62M
Balance Sheet
Total Assets0.0010.26B8.80B7.93B7.42B7.90B
Cash, Cash Equivalents and Short-Term Investments888.99M888.99M774.10M379.90M41.68M292.11M
Total Debt0.001.23B1.10B1.05B929.59M965.67M
Total Liabilities-6.44B3.82B2.70B2.20B2.00B1.76B
Stockholders Equity6.44B6.44B6.10B5.73B5.42B6.13B
Cash Flow
Free Cash Flow0.0096.61M478.18M358.18M-39.70M-104.86M
Operating Cash Flow0.00175.81M745.94M383.67M170.46M11.13M
Investing Cash Flow0.00-39.62M-274.01M-28.84M-198.66M-102.82M
Financing Cash Flow0.00-21.30M-77.78M-16.68M-222.27M164.01M

Nath Bio-Genes (India) Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price169.10
Price Trends
50DMA
171.35
Positive
100DMA
183.97
Negative
200DMA
174.09
Negative
Market Momentum
MACD
0.02
Negative
RSI
51.18
Neutral
STOCH
27.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 169.1 is below the 20-day moving average (MA) of 170.69, below the 50-day MA of 171.35, and below the 200-day MA of 174.09, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.18 is Neutral, neither overbought nor oversold. The STOCH value of 27.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
₹5.16B14.040.30%19.25%67.58%
65
Neutral
₹3.25B8.021.19%18.61%4.02%
64
Neutral
₹4.18B15.42
63
Neutral
₹3.64B13.778.73%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:NATHBIOGEN
Nath Bio-Genes (India) Ltd.
172.60
-8.12
-4.49%
IN:ARIES
Aries Agro Ltd.
400.15
173.81
76.79%
IN:CONTI
Continental Seeds & Chemicals Ltd.
24.25
-14.70
-37.74%
IN:GOODRICKE
Goodricke Group Ltd
192.20
-62.80
-24.63%
IN:HARRMALAYA
Harrisons Malayalam Ltd
202.55
-69.40
-25.52%
IN:NOVAAGRI
Nova Agritech Limited
46.13
-10.84
-19.03%

Nath Bio-Genes (India) Ltd. Corporate Events

Nath Bio-Genes Ensures Regulatory Compliance with SEBI Regulations
Oct 15, 2025

Nath Bio-Genes (India) Ltd. has submitted a compliance certificate for the quarter ending September 30, 2025, in accordance with SEBI (Depositories and Participants) Regulations, 2018. This submission, confirmed by their Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd., ensures that all securities received for dematerialization have been processed and listed appropriately, maintaining regulatory compliance and transparency for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 25, 2025